Renal Osteodystrophy in Chronic Kidney Disease When Vitamin D Analog Therapy Has Failed to Suppress PTH

Clinical scenario

Adults with chronic kidney disease (CKD stages G3a–G5) not on dialysis, in whom intact parathyroid hormone (PTH) is progressively rising or remains persistently above the upper normal limit for the assay despite prior intervention.

Why this protocol applies — prior line did not achieve goals

The previous step involved calcitriol or vitamin D analogs (reserved for CKD G4–G5 with severe and progressive hyperparathyroidism, titrated based on PTH response). The goal — suppression of intact PTH without hypercalcemia — was not achieved, indicating failure of medical or pharmacological management and the need to escalate.

Next-line approach (partial — full protocol behind the link)

For patients who have not responded to medical or pharmacological therapy, a surgical approach is considered. The complete criteria, patient selection details, and procedural guidance are in the full protocol.

Treatment goal

Reduction of serum parathyroid hormone.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1038/ki.2009.191

In patients with CKD G3a–G5 not on dialysis, the optimal PTH level is not known. However, we suggest that patients with levels of intact PTH progressively rising or persistently above the upper normal limit for the assay be evaluated for modifiable factors, including hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency (2C).

In patients with CKD G3a–G5D with severe hyperparathyroidism (HPT) who fail to respond to medical or pharmacological therapy, we suggest parathyroidectomy (2B).

View source ↗